Inflammatory bowel disease negatively affects the quality of life of millions of patients around the world. Although the precise etiology of the disease remains elusive, aberrant immune system activation is an underlying cause. As such, therapies that selectively inhibit immune cell activation without broad immunosuppression are desired.
utilizing efferent signaling from the vagus nerve to the lymphoid organs to reduce inflammation and damage. With clinical trials using neurostimulation devices to activate the efferent arm of the CAIP already reported in patients suffering from inflammatory bowel disease (IBD), [5] [6] [7] better characterization of this reflex is required.
There are currently an estimated 4-4.5 million people in the United
States and Europe 8 that are afflicted with IBD, characterized by chronic inflammation resulting in abdominal pain, fever, diarrhea, fatigue, and rectal bleeding. 9 Current therapeutic modalities generally seek to reduce inflammation and include non-steroidal anti-inflammatory drugs, biologicals targeted to specific cytokines, or surgical intervention. 10, 11 While monoclonal antibodies directed against TNFα have greatly advanced the treatment of IBD, 10 these therapeutics increase the risk of infection and can lose efficacy overtime. 9, 11, 12 With this in mind novel therapeutic approaches targeting the molecular underpinnings of disease are in high demand. 13 Experimental modeling of IBD can be accomplished in a variety of well-characterized spontaneous or induced mouse models. 14 Although spontaneous disease models have yielded important insights into disease, variability in disease severity and penetrance can impose significant limitations. 14 Recognizing these limitations, induced models of colitis that each uniquely recapitulate certain aspects of pathology in patients have been developed. These include acute exposure to the chemical irritant dextran sodium sulfate (DSS), and adoptive transfer of colitogenic T-cells. [14] [15] [16] DSS is toxic to intestinal epithelial cells (IEC)
resulting in a denuded epithelium and inflammation in the mid-distal colon because of recruitment and activation of monocytes/macrophages and neutrophils, [17] [18] [19] without requiring T-cells. 20 Although this colitis model has provided detailed mechanisms of neutrophil recruitment, and mucosal wound healing, the T-cell independent nature of pathology is divergent from clinical presentation. Consequently, an induced T-cell dependent colitis model was developed using adop-
14 It is important to consider that therapeutics that reduce disease severity or do not appear efficacious in one model may only reflect an inability to modulate a specific aspect of disease.
The study by Willemze et al. 21 in the current issue of
Neurogastroenterology & Motility significantly adds to the growing knowledge base on the regulation of inflammation by the nervous system, demonstrating that the superior mesenteric, but not the vagus nerve, control the inflammatory response during acute DSS-induced colitis.
Identification of this specific functional neuroimmune circuit that controls inflammation in a preclinical model of IBD has the potential to allow for development of highly targeted and efficacious electroceuticals.
| CHOLINERGIC ANTI-INFLAMMATORY PATHWAY VS. SYMPATHETIC REGULATION OF IMMUNITY
The vagus nerve is the longest cranial nerve in the parasympathetic nervous system, composed of 70-80% afferent and 20-30% efferent signaling. The nerve innervates many peripheral organs, and maintains several physiological mechanisms, including digestion, heartbeat, immune responses, hormone secretion and respiratory function.
Recently, the ability of efferent signaling from this nerve in controlling inflammation has been the focus of a growing body of research. Corroborating studies confirmed this ability of VNS to reduce inflammation with vagotomy worsening colitis severity. 33, 34 Suggesting that there could be a similar α7R mediated mechanism in reducing colitis severity, peripheral administration of nicotine as a non-selective nicotinic receptor agonist ameliorated disease in mice previously subjected
Key Points
• Intestinal inflammation can be inhibited following electrical neural stimulation.
• There are multiple neural immune inhibitory circuits, with some appearing to be unique to the targeted organ.
• The promise of neural stimulation as a therapeutic will be enhanced by better characterization of these functional circuits.
to vagotomy. 26, 27 These data suggested the importance of the role of ACh receptors as targets that could reduce intestinal inflammation.
Despite these seminal findings and ongoing clinical trials, there are still large gaps in our knowledge concerning the functional circuitry and mechanisms of action in the inhibition of colonic inflammation by the nervous system. Several studies have questioned the proposed neuro-immune circuit; with conflicting evidence of a connection between the efferent vagus and celiac ganglia. Neuroanatomical tracing studies using injection of DiI in the dorsal motor nucleus and fast blue in the spleen have failed to identify co-labeled cell bodies in the celiac ganglia. 35 Electrical stimulation of the vagus in these studies was also found to have no stimulatory effect on splenic nerve activity. 35 Adding to this controversy, viral tracing using injection of pseudorabies virus has generated evidence in support of a vagus-to-spleen, 36 or a sympathetic ganglia-central nervous system pathway. 37 As further evidence of a sympathetic pathway to inhibit macrophage activation, LPS-induced TNFα production was significantly increased in mice with bilateral ablation of the splanchnic sympathetic nerves but not vagotomy. 
24,41
Based on the observations that VNS reduced dendritic cell activation, and vagotomy increased DSS-induced DC activation
28
; it would seem reasonable to investigate how stimulation or removal of basal sympathetic signaling would affect the secondary lymphoid organs that drain the small intestine and colon. As these tissues are critical for the induction of oral tolerance, host defense, and generation of immunopathological responses, 42 understanding how the nervous system affects these organs will be crucial to applying neuromodulation for intestinal immunopathology. It should be noted that the lymph nodes draining the small intestine and colon are discrete tissues that are anatomically separate with unique functions. 42 Not only are the mesenteric lymph nodes divided into small intestinal or colonic draining, the iliac LN function to drain the distal colon. 43 In addition, each of these LN receive unique phenotypes of DC homing from these different regions of the intestine, imparting different T-cells responses. 42 
| MECHANISMS OF SMN-MEDIATED IMMUNE MODULATION
Sympathetic neurotransmitters such as NE have been well established to increase or reduce immune cell activation. Although it is beyond the scope of this article to detail these studies, there are several comprehensive reviews that describe these receptors expressed by different immune cell populations and the functional consequences signaling activated through these pathways. TNFα production, selective agonists of α-AR receptors augment TNFα production in vitro 51 and in vivo. 52 In the context of intestinal inflammation, blockade of α2-AR significantly reduced weight loss, proinflammatory cytokine production and histological damage in TNBS induced colitis. 53 In keeping with the presumed anti-inflammatory role of the β-AR, administration of a β3-AR agonist significantly reduced the severity of an induced colitis in rats. 54 Despite these results that generally corroborate the pro-and anti-inflammatory role of α-AR and 
| CLINICAL TRIALS; CLINICAL CHALLENGES AND OPPORTUNITIES
With these generally positive results in preclinical models of septic shock, 4 intestinal inflammation, 26, 27 there has been a substantial effort to translate these findings into therapeutics. 57 In the clinical setting, VNS typically refers to a helical or cuff electrode surgically placed on the left cervical vagus nerve that is then connected to a stimulus unit.
In general, several clinical trials have produced promising albeit mixed results, conceivably because of the gaps in knowledge surrounding the critical stimulation parameters and mechanisms behind which VNS exerts an effect.
In a study with seven patients with Crohn's disease, VNS was applied by a spiral electrode wrapped around the left cervical vagus, with initial stimulation at 0.25 mA increasing to 1.25 mA for 6 months.
Once the trial had ended, five patients saw improvements in symptoms and four of those five had entered remission. It should be noted that two of the seven patients were withdrawn from the study, because of a worsening of the disease, though these individuals had worse disease scores prior to treatment than the other patients. 5 As the electrode was well-tolerated and no significant adverse events were observed, these results highlight the promise of a safe and efficacious new therapy. Curiously, the effect of pre-existing and often chronic inflammation on the success of VNS in treatment of inflammation does not appear to have been addressed a variable. Acute colonic inflammation in DSS-induced colitis significantly reduces the evoked neurotransmitter release from sympathetic neurons in the superior mesenteric ganglia, and in the intestine. 58, 59 These results would suggest that efficacy of therapeutic VNS for inflammatory disease such as IBD could vary between patients depending on the severity and state of disease at treatment initiation. Despite the potential importance of this variable, this aspect does not appear to have been assessed in either preclinical or clinical studies.
The invasiveness of electrode implantation has also led to the design and implementation of a non-invasive methodology for VNS.
Preclinical studies have demonstrated the efficacy of transcutaneous vagal nerve stimulation (tcVNS), where the electrode is placed externally on the side of the neck during stimulation, in the control of inflammation. 60 This approach also appears to be effective clinically, as peripheral blood mononuclear cells from health volunteers stimulated with tcVNS produced significantly less pro-inflammatory cytokines compared to non-stimulated when challenged ex vivo with LPS. 6 As another alternative to wrapping of the electrode, transvenous stimulation has also been attempted. In this procedure the electrode is placed using a catheter on the left internal jugular vein near the vagus.
While this method of VNS is less invasive than implantation of a cuff electrode and was well-tolerated by the subjects; VNS did not reduce pro-inflammatory cytokine production or prevent LPS (2 ng/kg i.v.) induced fever, flu-like symptoms and increased heart rate. Additionally, when whole blood samples taken from the subjects were challenged with LPS ex vivo, VNS failed to reduce inflammatory cytokine release. This type of modeling has recently been applied to understanding the failure of kilohertz frequency blockade to achieve primary clinical endpoints as a therapy in obesity. 61 Such analysis indicated that the selected parameters based on prior assumptions of electrophysiological properties of the nerve would appear to be ineffective, or could result in stimulation rather than blockade. 61 With the use of unique electrodes, electrode placement, and stimulation parameters perhaps the variability in clinical outcomes should not be surprising. These issues remain unique challenges and opportunities for the continued development of therapeutic electroceutical device for practical application in the clinic.
| CONCLUSION
The interaction and complex communication between the nervous and immune systems has the potential to be translated into novel and effective therapeutic in the treatment of IBD. With largely positive results accumulating from preclinical, and select clinical trials, this is a truly exciting time in the field of electroceuticals. Despite these successes, there remains several challenges and opportunities in the field.
These include rectifying seemingly inconsistent findings, functional circuits in different organ systems and animal species, and a thorough understanding of how electrode design and stimulation parameters can be best suited to stimulate specific nerves. Finally, as these therapies are designed for treatment of patients with chronic inflammation, the effect of disease on neuronal signaling should be addressed. The future and potential promise of neural stimulation as a novel therapeutic for these diseases depends on this research.
